F10 and cancer: In the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) sub-study, Fanola CL et al. compared 1153 patients who developed a new or recurrent malignancy and were taking either edoxaban 30 mg (31.9% of patients) or edoxaban 60 mg (33.8%) vs. warfarin (34.3%).